Navigation Links
Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
Date:11/15/2012

ares our vision for ITCA 650 in the diabetes marketplace, but has also expressed its confidence in our ability to shepherd ITCA 650 successfully through clinical trial development and to strike the collaborations needed to make ITCA 650 a global market success."

Robert R. Henry, M.D., Professor of Medicine at the University of California, San Diego, Chief, Section of Diabetes, Endocrinology and Metabolism at the VA San Diego Healthcare System, and immediate Past President of the American Diabetes Association, commented: "I am excited about this progress for ITCA 650, as it facilitates the launch of a global Phase 3 program and advances this innovative therapy towards the many patients I believe may benefit from improved efficacy, tolerability, and the ensured compliance and long-term control that could come from a once-yearly therapy. The trials could demonstrate a real treatment breakthrough for patients and, given the global scale of unmet needs in type 2 diabetes, I believe the entire community should be enthusiastic about research like this and potential products like ITCA 650."

The completed financing will also facilitate the previously announced move of Intarcia's corporate headquarters to the Boston, Mass. area, while keeping its early development capabilities and state-of-the-art manufacturing site at its current location in Hayward, California.

Morgan Stanley acted as sole structuring advisor to Intarcia for the transaction. In addition, Morgan Stanley acted as sole placement agent for the debt and lead placement agent for the equity. Leerink Swann LLC acted as co-placement agent on the equity.

About ITCA 650

ITCA 650 (continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... 2014 Gain recognition for leadership ... of the biotech industry. Nominations are now being ... to you by the Bio Supply Management ... chain management professionals for the past 7 years. ... the Biotech industry – Manufacturers, Service Providers, Material ...
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... Sept. 7 Alba Therapeutics Corporation today,announced the ... Senior Vice,President, Clinical Development and Medical Affairs. In ... leading Alba,s clinical development strategy,and program execution through ... serve as a member of Alba,s executive management,leadership ...
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... today announced that it will deliver poster,presentations at ... its anti-cancer antibody drug candidates. At the ... September 7-8,Arius will report recent results of its ...
... 1959, Nobel Prize winner Richard Feynman presented a talk entitled ... that there was no physical reason why humans couldn,t manipulate ... of observing the new atom positions remains. How do ... the Sept. 7, 2007 issue of Science, IBM and Imago ...
Cached Biology Technology:Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 3IBM and Imago find a crucial difficulty in semiconductor device scaling 2
(Date:7/25/2014)... CORAL SPRINGS, Florida , July 25, 2014 /PRNewswire/ ... influential as more consumers are turning to digital technology ... NXT-ID, Inc. (OTCBB: NXTD), Google Inc. (NASDAQ: ... Visa Inc. (NYSE: V ), Apple Inc. ... FTNT) NXT-ID, Inc., (OTCQB: NXTD) a biometric ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
(Date:7/24/2014)... disturbance has different effects on different species of ... Universities of Bristol and Exeter which tested fish ... to a flying seagull predator model when exposed ... in European minnows. , Lead author Dr ... said: "Noise levels in many aquatic environments have ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... receive a special discretionary prize, as part of the ... The European Molecular Biology Organization (EMBO) awards the prize ... communication with the public. The additional award was made ... a single organism using all available media. , ...
... Barbara, Calif.) It,s no secret that humans are having ... animals. UC Santa Barbara,s Steven D. Gaines and fellow researcher ... world,s far-flung islands. Their research, published this month in ... sheds surprising light on the subject of extinction rates of ...
... Organization (EMBO) announced that the German evolutionary biologist Axel ... the 2008 EMBO Award for Communication in the Life ... scientist in Europe for outstanding communication with the public. ... continuous endeavour to convey complex scientific topics to the ...
Cached Biology News:EMBO recognizes German zoologist for public communication 2Study of islands reveals surprising extinction results 2Study of islands reveals surprising extinction results 3Prominent German biologist wins EMBO Communication Award 2
... The excellent isocratic refractive index chromatography system, ... CE 4700. Data processing is provided ... delivery is by the high pressure CE 4100 ... can be supplied. The system can ...
...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
...
Biology Products: